$XBI $89.00 | +8.67%
Covid Updates
$TFFP TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2
$MRNA Moderna - EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
$PFE Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union
$VXRT Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates
Pipeline Updates
$BDSI BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine
$ADIL ADIAL PHARMACEUTICALS ANNOUNCES COMPLETION OF LAST PATIENT, LAST VISIT IN ITS ONWARD™ PHASE 3 TRIAL OF AD04 FOR THE TREATMENT OF PATIENTS WITH ALCOHOL USE DISORDER
$PDSB Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union
$CYCN Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
$PLRX Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
$AQST Aquestive Therapeutics Announces FDA Clearance Of Investigational New Drug Application (IND) For AQST-109 Epinephrine Oral Film
$RYTM Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
$ARWR Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
$AMRN JAMA PUBLICATION HIGHLIGHTS VASCEPA® (ICOSAPENT ETHYL) CARDIOVASCULAR RISK REDUCTION EXTENDS TO COST EFFECTIVENESS AT PATIENT LEVEL
$CNTA Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
$CMRX Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research
$CLNN Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022.
$BCRX BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)
$MNKD Update on Tyvaso DPI™ New Drug Application.
$RNLX KidneyIntelXTM Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care.
Business Updates
$ARDX Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners
Posted by DV
Comments